0001193125-23-205527.txt : 20230808 0001193125-23-205527.hdr.sgml : 20230808 20230808064527 ACCESSION NUMBER: 0001193125-23-205527 CONFORMED SUBMISSION TYPE: 8-K PUBLIC DOCUMENT COUNT: 16 CONFORMED PERIOD OF REPORT: 20230802 ITEM INFORMATION: Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers: Compensatory Arrangements of Certain Officers ITEM INFORMATION: Regulation FD Disclosure ITEM INFORMATION: Financial Statements and Exhibits FILED AS OF DATE: 20230808 DATE AS OF CHANGE: 20230808 FILER: COMPANY DATA: COMPANY CONFORMED NAME: Elevance Health, Inc. CENTRAL INDEX KEY: 0001156039 STANDARD INDUSTRIAL CLASSIFICATION: HOSPITAL & MEDICAL SERVICE PLANS [6324] IRS NUMBER: 352145715 STATE OF INCORPORATION: IN FISCAL YEAR END: 1231 FILING VALUES: FORM TYPE: 8-K SEC ACT: 1934 Act SEC FILE NUMBER: 001-16751 FILM NUMBER: 231149214 BUSINESS ADDRESS: STREET 1: 220 VIRGINIA AVENUE CITY: INDIANAPOLIS STATE: IN ZIP: 46204 BUSINESS PHONE: 8003311476 MAIL ADDRESS: STREET 1: 220 VIRGINIA AVENUE CITY: INDIANAPOLIS STATE: IN ZIP: 46204 FORMER COMPANY: FORMER CONFORMED NAME: Anthem, Inc. DATE OF NAME CHANGE: 20141202 FORMER COMPANY: FORMER CONFORMED NAME: WELLPOINT, INC DATE OF NAME CHANGE: 20100105 FORMER COMPANY: FORMER CONFORMED NAME: WELLPOINT INC DATE OF NAME CHANGE: 20041130 8-K 1 d492032d8k.htm 8-K 8-K
IN false 0001156039 0001156039 2023-08-02 2023-08-02

 

 

UNITED STATES

SECURITIES AND EXCHANGE COMMISSION

Washington, D.C. 20549

 

 

FORM 8-K

 

 

CURRENT REPORT

Pursuant to Section 13 or 15(d)

of the Securities Exchange Act of 1934

August 8, 2023 (August 2, 2023)

Date of Report (Date of earliest event reported)

 

 

Elevance Health, Inc.

(Exact name of registrant as specified in its charter)

 

 

 

Indiana   001-16751   35-2145715

(State or other jurisdiction of

incorporation or organization)

  

(Commission

File Number)

  

(IRS Employer

Identification No.)

220 Virginia Ave

Indianapolis, IN 46204

(Address of principal executive offices and zip code)

833-401-1577

(Registrant’s telephone number, including area code)

 

 

Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions:

 

  ☐

Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)

 

  ☐

Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)

 

  ☐

Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))

 

  ☐

Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))

Securities registered pursuant to Section 12(b) of the Act:

 

Title of each class

  

Trading

Symbol

  

Name of each exchange

on which registered

Common Stock, Par Value $0.01   ELV   New York Stock Exchange

Indicate by check mark whether the registrant is an emerging growth company as defined Rule 405 of the Securities Act (§230.405 of this chapter) or Rule 12b-2 of the Exchange Act (§240.12b-2 of this chapter).

Emerging growth company  ☐

If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act.  ☐

 

 

 

Item 5.02 - Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers; Compensatory Arrangements of Certain Officers.

On August 8, 2023, Elevance Health, Inc. (the “Company”) announced that Mark Kaye has been named Executive Vice President and Chief Financial Officer (“CFO”) of the Company, effective November 1, 2023 (the “Transition Date”). Mr. Kaye will commence employment with the Company on September 6, 2023 as CFO Designate prior to assuming the CFO position on the Transition Date. Mr. Kaye succeeds John Gallina, who, after nearly thirty years of dedicated services to the Company, has decided to retire as CFO. Mr. Gallina will continue to be employed by the Company in the new role of Special Advisor to the Chief Executive Officer from the Transition Date.

Mr. Kaye, age 44, joins the Company from Moody’s Corporation, where he served as the Executive Vice President and Chief Financial Officer since April 2021 and as Senior Vice President and Chief Financial Officer from August 2018 to April 2021. Prior to his role at Moody’s Corporation, Mr. Kaye was Senior Vice President and Head of Financial Planning and Analysis at Massachusetts Mutual Life Insurance Company (“MassMutual”) since February 2016 and Chief Financial Officer of MassMutual U.S. since July 2015. Prior to that, Mr. Kaye served as Chief Financial Officer and Senior Vice President, Retirement Solutions, at Voya Financial from 2011 to 2015. Mr. Kaye previously held various senior financial and risk reporting positions at ING U.S. and ING Group, and was in the investment banking division of Credit Suisse First Boston.

On August 2, 2023, Mr. Kaye accepted a written offer letter from the Company establishing his compensation (the “Offer Letter”). Mr. Kaye’s initial compensation will consist of (i) an annual base salary of $900,000, (ii) a target annual incentive bonus opportunity equal to 120% of eligible base salary earnings and (iii) long-term incentive awards with an annual aggregate target value equal to $5,500,000 beginning in 2024. Mr. Kaye will also participate in the Company’s Directed Executive Compensation Program (“DEC”).

To compensate Mr. Kaye for unvested equity he will forfeit when he departs his current employer and to provide a prorated long-term incentive award for 2023, Mr. Kaye will receive a one-time award of equity with a value of $8,000,000 in restricted stock units. Mr. Kaye will also receive a prorated 2023 long-term incentive award of $3,700,000 in a mixture of restricted stock units, performance stock units and stock options. These one-time equity awards will be subject to the terms and conditions of the 2017 Elevance Health Incentive Compensation Plan, as amended and restated effective June 28, 2022, and the individual award agreement corresponding to the award. One-third of the restricted stock units and one-third of the stock options subject to these one-time equity awards will vest on each of the first, second, and third anniversaries of the date of grant, assuming Mr. Kaye’s continued employment by the Company through each such date, subject to the terms of the applicable award agreement. The performance stock units vest in 2026 based on the level of achievement of Company performance from 2023 through 2025 in accordance with the terms of the performance stock units granted to the Company’s senior officers in 2023.

In addition, to compensate Mr. Kaye for forfeited bonus payments and other incentives from his current employer, the Company will provide Mr. Kaye with a one-time cash award of $2,500,000, which will be paid to him on his first paycheck after Mr. Kaye’s start date. Mr. Kaye will be required to repay this cash bonus if he voluntarily resigns or is terminated for cause within three years of his start date.

Pursuant to the Offer Letter, Mr. Kaye will participate in the Elevance Health Executive Agreement Plan, as amended and restated effective June 28, 2022 (the “Executive Agreement Plan”), at the Executive Vice President level, which provides for severance benefits following a termination of employment without cause or resignation for good reason consisting of two years of salary and target bonus, as well as continued employee benefits and DEC benefits during the severance period. Additionally, the Executive Agreement Plan provides for accelerated vesting of equity grants upon a termination of employment without cause or for good reason within three years following a change in control. Mr. Kaye will be subject to certain restrictive covenants including confidentiality, non-competition, non-solicitation and non-disparagement during his employment and for specified periods of time after the termination of his employment.

The foregoing description of Mr. Kaye’s Offer Letter is qualified in its entirety by reference to Mr. Kaye’s Offer Letter, a copy of which is filed as Exhibit 10.1 to this report and is incorporated herein by reference.

There are no arrangements or understandings between Mr. Kaye and any other persons pursuant to which he was selected as Chief Financial Officer. There are no family relationships between Mr. Kaye and any director or executive officer of the Company, and Mr. Kaye has no direct or indirect material interest in any transaction required to be disclosed pursuant to Item 404(a) of Regulation S-K.

 

Item 7.01 – Regulation FD Disclosure

A copy of the press release issued by the Company on August 8, 2023 announcing Mr. Kaye’s appointment as Executive Vice President and Chief Financial Officer effective on the Transition Date is furnished as Exhibit 99.1 to this report.

The Company is reaffirming its net income guidance for full year 2023 to be greater than $29.09 per share, including approximately $3.76 per share of net unfavorable items. Excluding these items, the Company continues to expect adjusted net income to be greater than $32.85 per share. This guidance does not include any other adjustment items beyond those reported in the Company’s second quarter 2023 earnings release.

None of the information furnished in Item 7.01 or Exhibit 99.1 hereto shall be deemed to be “filed” for purposes of Section 18 of the Securities Exchange Act of 1934, as amended. Unless expressly set forth by specific reference in such filings, none of the information furnished in this report shall be incorporated by reference in any filing under the Securities Act of 1933, as amended, whether made before or after the date hereof and regardless of any general incorporation language in such filings.

Item 9.01 – Financial Statements and Exhibits

 

Exhibit
No.

   

Exhibit

10.1    Offer Letter, dated August 2, 2023, between Mark Kaye and Elevance Health, Inc.
99.1   

Press Release, dated August 8, 2023.

104    Cover Page Interactive Data File (embedded within the Inline XBRL document).

SIGNATURE

Pursuant to the requirements of the Securities Exchange Act of 1934, as amended, the Registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized on this 8th day of August, 2023.

 

ELEVANCE HEALTH, INC.
By:  

/s/ Kathleen S. Kiefer

Name:   Kathleen S. Kiefer
Title:   Chief Governance Officer and Corporate Secretary
 EX-10.1 2 d492032dex101.htm EX-10.1 EX-10.1

Exhibit 10.1

 

LOGO

August 2, 2023

Mark Kaye

Sent Via Email

Dear Mark:

On behalf of the Board and me, I am pleased to provide the following offer of employment to you as Chief Financial Officer reporting to Gail Boudreaux. This position will be based out of our 220 Virginia Avenue, Indianapolis, Indiana office and your start date will be September 6, 2023. You will be CFO Designate from your start date until November 1, 2023, at which time you will assume the CFO position. We are very enthusiastic about you joining our team!

I am pleased to advise you that the starting compensation and benefits for this position are as follows:

 

  •  

An annualized base salary of $900,000 paid bi-weekly, one week in arrears.

 

  •  

Participation in the Annual Incentive Plan (AIP) with a target award of 120% of your eligible earnings as defined in the AIP; your eligible earnings will generally be the base salary that is paid to you during the calendar year. The AIP provides you with an opportunity to earn an award based on goals set at the beginning of each year.

 

  •  

Participation in Elevance Health’s annual Long Term Stock Incentive program beginning in the calendar year following your hire date with a target amount of $5,500,000. There is no guarantee of future grants, but the company has typically provided grants to eligible associates each March. The actual amount granted reflects the level of your job and management’s review of your performance and contributions. Grants are made using a mix of grant types including restricted stock, performance stock and stock options, which typically vest within three years.

Stock grants are awarded pursuant to Elevance Health’s Incentive Compensation Plan and require accepting all terms and conditions including, but not limited to a confidentiality obligation, a prohibition from obtaining a competitive position in a restricted territory performing a restricted activity with a competitor (as these terms are defined in the grant agreement), a prohibition from soliciting associates or customers to leave Elevance Health, a prohibition on disparaging Elevance Health, and a cooperation clause.

 

  •  

You will receive a stock grant with a value of approximately $3,700,000 on the first business day of the month following or coinciding with your hire date. You will receive 50% of your grant in the form of performance stock units (PSUs).

Additionally, 25% of your grant will be in the form of restricted stock units (RSUs) and the final 25% in stock options. These grants will vest within three years assuming your continued service.

  •  

You will receive a second sign-on grant with a value of approximately $8,000,000 also the first business day of the month following or coinciding with your hire date. You will receive 100% of this grant in the form of RSUs, vesting in equal installments on the first, second and third anniversary of the grant.

In order to accept your grants, you must electronically accept the grant agreements through E*TRADE at any time within ninety (90) days after the Grant Date. If you do not timely and electronically accept the agreements, they will be null and void as of the 90th day after the grant date and you will have no right or claim to your stock grants.

 

  •  

You will receive a sign-on bonus in the total gross amount of $2,500,000 on the first paycheck following your start date. This payment will be subject to all applicable taxes and withholdings. If you voluntarily resign or are terminated for Cause within thirty-six (36) months of your start date, you agree to reimburse Elevance Health the full amount of this sign-on bonus. Cause is defined as (1) a violation of conduct as such term is defined in the Elevance Health HR Corrective Action Policy, and/or (2) the “Cause” definition in Section 8.1.3 of the Executive Agreement Plan.

 

  •  

You will be eligible for associate and executive Rewards & More programs. A few of these benefits are highlighted below; for additional details please go to benefitsatelevancehealth.com. Additionally, please refer to the enclosed Executive Rewards & More Benefits brochure. Executive Services will be contacting you shortly after your start date to schedule a time to answer any questions you may have.

 

  —

A cafeteria-style benefits plan offering medical, dental and vision coverage, life and long-term disability insurance, and medical and dependent care spending account options from which you can choose to best meet your, and your family’s needs. As a full-time associate, you are eligible for this coverage the first day of the month following employment.

 

  —

The Directed Executive Compensation (DEC) Program provides $30,000 annually in an equal combination of cash and core credits, prorated in 2023 based on your hire date. Cash credits will be paid on the first pay of each month and can be used at your discretion. Core credits will reimburse you for costs associated with allowable expenses such as financial and investment counseling, tax advice and preparation, estate planning and other advisory services.

 

  —

The Elevance Health 401(k) Plan includes a company match of 100% of your contributions on the first 4%, and 50% on the next 2% of your eligible earnings. You will be eligible to participate in the plan and Elevance Health will begin matching your contributions 30 days after your first day of employment. You will be 100% vested in your matching contributions on the second anniversary of your employment.

 

  —

The Elevance Health Deferred Compensation Plan allows you to save for future needs by deferring salary and bonus in excess of IRS limits and accumulating investment earnings tax-free until distribution. Additionally, Elevance Health will match contributions into this plan at the same rate as they are made in the 401(k) Plan.

 

2

  —

The Employee Stock Purchase Plan (ESPP) will offer you the opportunity to accumulate contributions through payroll deductions and purchase Elevance Health stock.

 

  —

Participation in the Executive Physical Program, a benefit worth over $2,000, offering comprehensive physicals every 12 or 24 months, depending on your age.

 

  —

Paid Time Off (PTO) - Executives do not have a fixed number of PTO days, and no formal approvals or tracking of PTO is required. Executives may take PTO at their discretion as long as it does not conflict with performing their job responsibilities.

You are eligible for relocation benefits as outlined in the enclosed Relocation Guidelines. It is expected that you will relocate to Indiana within the first six (6) months of employment. If you resign within twenty-four (24) months of your hire date, you agree to reimburse Elevance Health a prorated share of all relocation expenses paid to you or on your behalf.

As a top-level executive of a public company, it is important that your interests and rewards are aligned with those of our shareholders. With this position, you will be subject to Elevance Health’s Stock Ownership Guidelines and will need to hold 300% of your annual salary in Elevance Health stock. Your progress towards achieving your stock ownership guideline will be reviewed on an annual basis, and you will have five years from your date of hire to meet the requirement.

Finally, I would like to offer you participation in the Elevance Health Executive Agreement Plan (the “Plan”), which provides for severance benefits consisting of twenty-four (24) months of salary and target bonus, outplacement services, and continued health benefits while receiving severance. Additional benefits are provided in the instance of a termination after a change in control of Elevance Health.

Elevance Health uses an electronic on-boarding tool to facilitate all of your pre-employment paperwork. Following your acceptance of this offer, you will receive a welcome email providing you with information regarding our on-boarding tool and your login information to access your customized new hire portal. This portal will contain documents and videos to further introduce you to the Elevance Health organization, important resources and benefits information. It also provides links for you to complete pre-employment activities, such as your online new hire forms. Additionally, there will also be some pre-employment tasks that push directly to your mailbox, please be sure to keep an eye out for these as well. Lillian Penn will be your point of contact throughout the on-boarding process. Please feel free to contact her at lillian.penn@elevancehealth.com with any questions.

We are making this offer because of your general skills and knowledge of the industry and not to obtain any confidential or proprietary information belonging to your current employer. In fact, as a condition of employment, you are expressly prohibited from providing or disclosing to Elevance Health, or any of its subsidiaries and related entities, and from relying upon or utilizing in the provision of services to Elevance Health, any confidential and proprietary information of your current employer. Instead, you are expected to utilize only your general skills, knowledge and abilities gained over the course of your education, career and business experiences. Any improper use or disclosure of confidential or proprietary information of another entity would be the basis for immediate termination of your employment.

 

3

By signing this letter, you are representing that you will not retain any originals, copies, duplicates, reproduction or excerpts of any confidential or proprietary information of your current employer, whether in hard copy, electronic or other format, and that you will return all such information to your current employer and otherwise comply with your obligations to that employer regarding its property and confidential information. In addition, upon hire, you will be asked to acknowledge that you did not retain any documents of your current employer.

This offer is contingent upon the following:

 

  •  

Your ability to furnish proof of your identity and legal right to work in the United States. Be sure to bring the required documents on your first day of work.

 

  •  

Review of employment agreements and documents related to restrictive covenants from your current or former employer.

Once again, I am very pleased to extend this offer of employment to you and hope you will decide to join us. If you have any questions with regard to your position or the content of this letter, please feel free to contact me.

Very truly yours,

Blair W. Todt

Executive Vice President Chief

Legal Officer and Chief

Administrative Officer

I hereby accept the offer of employment described in this letter.

 

/s/ Mark Kaye

      

8/2/2023

   
Mark Kaye       Date   

 

4

EX-99.1 3 d492032dex991.htm EX-99.1 EX-99.1

Exhibit 99.1

 

LOGO

Elevance Health Announces John Gallina to Retire as CFO

Mark Kaye named Executive Vice President, Chief Financial Officer

INDIANAPOLIS— August 8, 2023 – Elevance Health (NYSE: ELV) announced today that John Gallina will retire from his role as executive vice president and CFO later this year. Mark Kaye has been named executive vice president and CFO and will serve as a member of the company’s executive leadership team, reporting directly to Gail K. Boudreaux, President and CEO. Kaye will serve as CFO Designate from September 6 to November 1, 2023, when he will assume full responsibility for the role. Gallina will remain with Elevance Health serving as Special Advisor to the CEO following his retirement as CFO to ensure a seamless transition.

Gallina’s distinguished career in the finance and healthcare fields spans more than four decades with nearly 30 of those years at Elevance Health where he was appointed as CFO in 2016 leading all financial and actuarial functions for the company including procurement and corporate real estate. Prior to his role as CFO, Gallina served in several leadership roles at the company including Senior Vice President and Chief Financial Officer for the Commercial and Specialty Business Division; Senior Vice President, Chief Accounting Officer and Chief Risk Officer; Senior Vice President, Internal Audit and Continuous Improvement; and Chief Financial Officer of Comprehensive Health Services.

“On behalf of the entire Elevance Health team, I want to thank John for his contributions to our company over the last three decades. John has been a valued member of our organization who has successfully led our finance organization, navigated an ever-changing and dynamic healthcare landscape, and played an important role in our transformation to become a lifetime trusted health partner,” said Gail K. Boudreaux, President and CEO. “John’s commitment to improve the health of the people and communities we serve is a testament to his career at Elevance Health and the driving force behind his dedication to guide the company through its cultural transformation,” added Boudreaux.

Kaye joins Elevance Health from Moody’s Corporation, where he served as Chief Financial Officer with responsibility for all global finance activities. Kaye is a seasoned C-Suite executive with deep financial, actuarial, and business experience known for both his leadership and passion in creating and instilling a culture of excellence, and his commitment to long-term sustainability and inclusion. Before joining Moody’s in 2018, Kaye held a variety of leadership roles in strategic finance, financial planning and analysis, and large-scale project management, including at MassMutual Life Insurance Company, and Voya Financial.

“Mark is a well-respected leader with an extensive global finance background, who has significant experience in leveraging data-driven financial insight to support the execution of superior operational and strategic decisions, including growing and scaling businesses to drive success,” said Boudreaux. “With an innovative and customer first mindset coupled with his passion for fostering a high-performance culture, Mark will be a tremendous asset as we work to deliver on our purpose to improve the health of humanity. I’m pleased to welcome Mark to the Elevance Health team.”

Kaye holds an MBA in Finance and a BSE in Statistics and Actuarial Science from The Wharton School of Business and the University of Pennsylvania and is a Fellow of the Society of Actuaries.

About Elevance Health, Inc.

Elevance Health is a lifetime, trusted health partner fueled by its purpose to improve the health of humanity. The company supports consumers, families, and communities across the entire care journey – connecting them to the care, support, and resources they need to lead healthier lives. Elevance Health’s companies serve approximately 118 million people through a diverse portfolio of industry-leading medical, digital, pharmacy, behavioral, clinical, and complex care solutions. For more information, please visit www.elevancehealth.com or follow us @ElevanceHealth on Twitter and Elevance Health on LinkedIn.

Investor Relations:

Stephen Tanal

Stephen.tanal@elevancehealth.com

Media Relations:

Leslie Porras

Leslie.Porras@elevancehealth.com

EX-101.SCH 4 elv-20230802.xsd XBRL TAXONOMY EXTENSION SCHEMA 100000 - Document - Document and Entity Information link:calculationLink link:presentationLink link:definitionLink EX-101.LAB 5 elv-20230802_lab.xml XBRL TAXONOMY EXTENSION LABEL LINKBASE Cover [Abstract] Cover [Abstract] Entity Address, State or Province Entity Address, State or Province Amendment Flag Amendment Flag Entity Central Index Key Entity Central Index Key Document Type Document Type Document Period End Date Document Period End Date Entity Registrant Name Entity Registrant Name Entity Incorporation State Country Code Entity Incorporation State Country Code Entity File Number Entity File Number Entity Tax Identification Number Entity Tax Identification Number Entity Address, Address Line One Entity Address, Address Line One Entity Address, City or Town Entity Address, City or Town Entity Address, Postal Zip Code Entity Address, Postal Zip Code City Area Code City Area Code Local Phone Number Local Phone Number Written Communications Written Communications Soliciting Material Soliciting Material Pre Commencement Tender Offer Pre Commencement Tender Offer Pre Commencement Issuer Tender Offer Pre Commencement Issuer Tender Offer Security 12b Title Security 12b Title Trading Symbol Trading Symbol Security Exchange Name Security Exchange Name Entity Emerging Growth Company Entity Emerging Growth Company EX-101.PRE 6 elv-20230802_pre.xml XBRL TAXONOMY EXTENSION PRESENTATION LINKBASE GRAPHIC 7 g492032g0808020950246.jpg GRAPHIC begin 644 g492032g0808020950246.jpg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end GRAPHIC 8 g492032g0808021223781.jpg GRAPHIC begin 644 g492032g0808021223781.jpg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end XML 9 R1.htm IDEA: XBRL DOCUMENT v3.23.2
Document and Entity Information
Aug. 02, 2023
Cover [Abstract]  
Entity Address, State or Province IN
Amendment Flag false
Entity Central Index Key 0001156039
Document Type 8-K
Document Period End Date Aug. 02, 2023
Entity Registrant Name Elevance Health, Inc.
Entity Incorporation State Country Code IN
Entity File Number 001-16751
Entity Tax Identification Number 35-2145715
Entity Address, Address Line One 220 Virginia Ave
Entity Address, City or Town Indianapolis
Entity Address, Postal Zip Code 46204
City Area Code 833
Local Phone Number 401-1577
Written Communications false
Soliciting Material false
Pre Commencement Tender Offer false
Pre Commencement Issuer Tender Offer false
Security 12b Title Common Stock, Par Value $0.01
Trading Symbol ELV
Security Exchange Name NYSE
Entity Emerging Growth Company false
XML 10 d492032d8k_htm.xml IDEA: XBRL DOCUMENT 0001156039 2023-08-02 2023-08-02 IN false 0001156039 8-K 2023-08-02 Elevance Health, Inc. IN 001-16751 35-2145715 220 Virginia Ave Indianapolis 46204 833 401-1577 false false false false Common Stock, Par Value $0.01 ELV NYSE false EXCEL 11 Financial_Report.xlsx IDEA: XBRL DOCUMENT begin 644 Financial_Report.xlsx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end XML 12 Show.js IDEA: XBRL DOCUMENT // Edgar(tm) Renderer was created by staff of the U.S. Securities and Exchange Commission. Data and content created by government employees within the scope of their employment are not subject to domestic copyright protection. 17 U.S.C. 105. var Show={};Show.LastAR=null,Show.showAR=function(a,r,w){if(Show.LastAR)Show.hideAR();var e=a;while(e&&e.nodeName!='TABLE')e=e.nextSibling;if(!e||e.nodeName!='TABLE'){var ref=((window)?w.document:document).getElementById(r);if(ref){e=ref.cloneNode(!0); e.removeAttribute('id');a.parentNode.appendChild(e)}} if(e)e.style.display='block';Show.LastAR=e};Show.hideAR=function(){Show.LastAR.style.display='none'};Show.toggleNext=function(a){var e=a;while(e.nodeName!='DIV')e=e.nextSibling;if(!e.style){}else if(!e.style.display){}else{var d,p_;if(e.style.display=='none'){d='block';p='-'}else{d='none';p='+'} e.style.display=d;if(a.textContent){a.textContent=p+a.textContent.substring(1)}else{a.innerText=p+a.innerText.substring(1)}}} XML 13 report.css IDEA: XBRL DOCUMENT /* Updated 2009-11-04 */ /* v2.2.0.24 */ /* DefRef Styles */ ..report table.authRefData{ background-color: #def; border: 2px solid #2F4497; font-size: 1em; position: absolute; } ..report table.authRefData a { display: block; font-weight: bold; } ..report table.authRefData p { margin-top: 0px; } ..report table.authRefData .hide { background-color: #2F4497; padding: 1px 3px 0px 0px; text-align: right; } ..report table.authRefData .hide a:hover { background-color: #2F4497; } ..report table.authRefData .body { height: 150px; overflow: auto; width: 400px; } ..report table.authRefData table{ font-size: 1em; } /* Report Styles */ ..pl a, .pl a:visited { color: black; text-decoration: none; } /* table */ ..report { background-color: white; border: 2px solid #acf; clear: both; color: black; font: normal 8pt Helvetica, Arial, san-serif; margin-bottom: 2em; } ..report hr { border: 1px solid #acf; } /* Top labels */ ..report th { background-color: #acf; color: black; font-weight: bold; text-align: center; } ..report th.void { background-color: transparent; color: #000000; font: bold 10pt Helvetica, Arial, san-serif; text-align: left; } ..report .pl { text-align: left; vertical-align: top; white-space: normal; width: 200px; white-space: normal; /* word-wrap: break-word; */ } ..report td.pl a.a { cursor: pointer; display: block; width: 200px; overflow: hidden; } ..report td.pl div.a { width: 200px; } ..report td.pl a:hover { background-color: #ffc; } /* Header rows... */ ..report tr.rh { background-color: #acf; color: black; font-weight: bold; } /* Calendars... */ ..report .rc { background-color: #f0f0f0; } /* Even rows... */ ..report .re, .report .reu { background-color: #def; } ..report .reu td { border-bottom: 1px solid black; } /* Odd rows... */ ..report .ro, .report .rou { background-color: white; } ..report .rou td { border-bottom: 1px solid black; } ..report .rou table td, .report .reu table td { border-bottom: 0px solid black; } /* styles for footnote marker */ ..report .fn { white-space: nowrap; } /* styles for numeric types */ ..report .num, .report .nump { text-align: right; white-space: nowrap; } ..report .nump { padding-left: 2em; } ..report .nump { padding: 0px 0.4em 0px 2em; } /* styles for text types */ ..report .text { text-align: left; white-space: normal; } ..report .text .big { margin-bottom: 1em; width: 17em; } ..report .text .more { display: none; } ..report .text .note { font-style: italic; font-weight: bold; } ..report .text .small { width: 10em; } ..report sup { font-style: italic; } ..report .outerFootnotes { font-size: 1em; } XML 14 FilingSummary.xml IDEA: XBRL DOCUMENT 3.23.2 html 1 22 1 false 0 0 false 0 false false R1.htm 100000 - Document - Document and Entity Information Sheet http://www.elevancehealth.com//20230802/taxonomy/role/DocumentDocumentAndEntityInformation Document and Entity Information Cover 1 false false All Reports Book All Reports [ix-0514-Hidden-Fact-Eligible-For-Transform] WARN: 1 fact(s) appearing in ix:hidden were eligible for transformation: dei:EntityAddressStateOrProvince - d492032d8k.htm 7 d492032d8k.htm d492032dex101.htm d492032dex991.htm elv-20230802.xsd elv-20230802_lab.xml elv-20230802_pre.xml http://xbrl.sec.gov/dei/2022 true false JSON 17 MetaLinks.json IDEA: XBRL DOCUMENT { "instance": { "d492032d8k.htm": { "axisCustom": 0, "axisStandard": 0, "baseTaxonomies": { "http://xbrl.sec.gov/dei/2022": 22 }, "contextCount": 1, "dts": { "inline": { "local": [ "d492032d8k.htm" ] }, "labelLink": { "local": [ "elv-20230802_lab.xml" ] }, "presentationLink": { "local": [ "elv-20230802_pre.xml" ] }, "schema": { "local": [ "elv-20230802.xsd" ], "remote": [ "http://www.xbrl.org/2003/xbrl-instance-2003-12-31.xsd", "http://www.xbrl.org/2003/xbrl-linkbase-2003-12-31.xsd", "http://www.xbrl.org/2003/xl-2003-12-31.xsd", "http://www.xbrl.org/2003/xlink-2003-12-31.xsd", "http://www.xbrl.org/2005/xbrldt-2005.xsd", "http://www.xbrl.org/dtr/type/nonNumeric-2009-12-16.xsd", "http://www.xbrl.org/dtr/type/numeric-2009-12-16.xsd", "https://www.xbrl.org/dtr/type/2020-01-21/types.xsd", "https://xbrl.sec.gov/dei/2022/dei-2022.xsd", "https://xbrl.sec.gov/naics/2022/naics-2022.xsd" ] } }, "elementCount": 23, "entityCount": 1, "hidden": { "http://xbrl.sec.gov/dei/2022": 3, "total": 3 }, "keyCustom": 0, "keyStandard": 22, "memberCustom": 0, "memberStandard": 0, "nsprefix": "elv", "nsuri": "http://www.elevancehealth.com/20230802", "report": { "R1": { "firstAnchor": { "ancestors": [ "span", "p", "div", "div", "body", "html" ], "baseRef": "d492032d8k.htm", "contextRef": "duration_2023-08-02_to_2023-08-02", "decimals": null, "first": true, "lang": "en-US", "name": "dei:DocumentType", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" }, "groupType": "document", "isDefault": "true", "longName": "100000 - Document - Document and Entity Information", "menuCat": "Cover", "order": "1", "role": "http://www.elevancehealth.com//20230802/taxonomy/role/DocumentDocumentAndEntityInformation", "shortName": "Document and Entity Information", "subGroupType": "", "uniqueAnchor": { "ancestors": [ "span", "p", "div", "div", "body", "html" ], "baseRef": "d492032d8k.htm", "contextRef": "duration_2023-08-02_to_2023-08-02", "decimals": null, "first": true, "lang": "en-US", "name": "dei:DocumentType", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" } } }, "segmentCount": 0, "tag": { "dei_AmendmentFlag": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Boolean flag that is true when the XBRL content amends previously-filed or accepted submission.", "label": "Amendment Flag", "terseLabel": "Amendment Flag" } } }, "localname": "AmendmentFlag", "nsuri": "http://xbrl.sec.gov/dei/2022", "presentation": [ "http://www.elevancehealth.com//20230802/taxonomy/role/DocumentDocumentAndEntityInformation" ], "xbrltype": "booleanItemType" }, "dei_CityAreaCode": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Area code of city", "label": "City Area Code", "terseLabel": "City Area Code" } } }, "localname": "CityAreaCode", "nsuri": "http://xbrl.sec.gov/dei/2022", "presentation": [ "http://www.elevancehealth.com//20230802/taxonomy/role/DocumentDocumentAndEntityInformation" ], "xbrltype": "normalizedStringItemType" }, "dei_CoverAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Cover page.", "label": "Cover [Abstract]", "terseLabel": "Cover [Abstract]" } } }, "localname": "CoverAbstract", "nsuri": "http://xbrl.sec.gov/dei/2022", "xbrltype": "stringItemType" }, "dei_DocumentPeriodEndDate": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "For the EDGAR submission types of Form 8-K: the date of the report, the date of the earliest event reported; for the EDGAR submission types of Form N-1A: the filing date; for all other submission types: the end of the reporting or transition period. The format of the date is YYYY-MM-DD.", "label": "Document Period End Date", "terseLabel": "Document Period End Date" } } }, "localname": "DocumentPeriodEndDate", "nsuri": "http://xbrl.sec.gov/dei/2022", "presentation": [ "http://www.elevancehealth.com//20230802/taxonomy/role/DocumentDocumentAndEntityInformation" ], "xbrltype": "dateItemType" }, "dei_DocumentType": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "The type of document being provided (such as 10-K, 10-Q, 485BPOS, etc). The document type is limited to the same value as the supporting SEC submission type, or the word 'Other'.", "label": "Document Type", "terseLabel": "Document Type" } } }, "localname": "DocumentType", "nsuri": "http://xbrl.sec.gov/dei/2022", "presentation": [ "http://www.elevancehealth.com//20230802/taxonomy/role/DocumentDocumentAndEntityInformation" ], "xbrltype": "submissionTypeItemType" }, "dei_EntityAddressAddressLine1": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Address Line 1 such as Attn, Building Name, Street Name", "label": "Entity Address, Address Line One", "terseLabel": "Entity Address, Address Line One" } } }, "localname": "EntityAddressAddressLine1", "nsuri": "http://xbrl.sec.gov/dei/2022", "presentation": [ "http://www.elevancehealth.com//20230802/taxonomy/role/DocumentDocumentAndEntityInformation" ], "xbrltype": "normalizedStringItemType" }, "dei_EntityAddressCityOrTown": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Name of the City or Town", "label": "Entity Address, City or Town", "terseLabel": "Entity Address, City or Town" } } }, "localname": "EntityAddressCityOrTown", "nsuri": "http://xbrl.sec.gov/dei/2022", "presentation": [ "http://www.elevancehealth.com//20230802/taxonomy/role/DocumentDocumentAndEntityInformation" ], "xbrltype": "normalizedStringItemType" }, "dei_EntityAddressPostalZipCode": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Code for the postal or zip code", "label": "Entity Address, Postal Zip Code", "terseLabel": "Entity Address, Postal Zip Code" } } }, "localname": "EntityAddressPostalZipCode", "nsuri": "http://xbrl.sec.gov/dei/2022", "presentation": [ "http://www.elevancehealth.com//20230802/taxonomy/role/DocumentDocumentAndEntityInformation" ], "xbrltype": "normalizedStringItemType" }, "dei_EntityAddressStateOrProvince": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Name of the state or province.", "label": "Entity Address, State or Province", "terseLabel": "Entity Address, State or Province" } } }, "localname": "EntityAddressStateOrProvince", "nsuri": "http://xbrl.sec.gov/dei/2022", "presentation": [ "http://www.elevancehealth.com//20230802/taxonomy/role/DocumentDocumentAndEntityInformation" ], "xbrltype": "stateOrProvinceItemType" }, "dei_EntityCentralIndexKey": { "auth_ref": [ "r1" ], "lang": { "en-us": { "role": { "documentation": "A unique 10-digit SEC-issued value to identify entities that have filed disclosures with the SEC. It is commonly abbreviated as CIK.", "label": "Entity Central Index Key", "terseLabel": "Entity Central Index Key" } } }, "localname": "EntityCentralIndexKey", "nsuri": "http://xbrl.sec.gov/dei/2022", "presentation": [ "http://www.elevancehealth.com//20230802/taxonomy/role/DocumentDocumentAndEntityInformation" ], "xbrltype": "centralIndexKeyItemType" }, "dei_EntityEmergingGrowthCompany": { "auth_ref": [ "r1" ], "lang": { "en-us": { "role": { "documentation": "Indicate if registrant meets the emerging growth company criteria.", "label": "Entity Emerging Growth Company", "terseLabel": "Entity Emerging Growth Company" } } }, "localname": "EntityEmergingGrowthCompany", "nsuri": "http://xbrl.sec.gov/dei/2022", "presentation": [ "http://www.elevancehealth.com//20230802/taxonomy/role/DocumentDocumentAndEntityInformation" ], "xbrltype": "booleanItemType" }, "dei_EntityFileNumber": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Commission file number. The field allows up to 17 characters. The prefix may contain 1-3 digits, the sequence number may contain 1-8 digits, the optional suffix may contain 1-4 characters, and the fields are separated with a hyphen.", "label": "Entity File Number", "terseLabel": "Entity File Number" } } }, "localname": "EntityFileNumber", "nsuri": "http://xbrl.sec.gov/dei/2022", "presentation": [ "http://www.elevancehealth.com//20230802/taxonomy/role/DocumentDocumentAndEntityInformation" ], "xbrltype": "fileNumberItemType" }, "dei_EntityIncorporationStateCountryCode": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Two-character EDGAR code representing the state or country of incorporation.", "label": "Entity Incorporation State Country Code", "terseLabel": "Entity Incorporation State Country Code" } } }, "localname": "EntityIncorporationStateCountryCode", "nsuri": "http://xbrl.sec.gov/dei/2022", "presentation": [ "http://www.elevancehealth.com//20230802/taxonomy/role/DocumentDocumentAndEntityInformation" ], "xbrltype": "edgarStateCountryItemType" }, "dei_EntityRegistrantName": { "auth_ref": [ "r1" ], "lang": { "en-us": { "role": { "documentation": "The exact name of the entity filing the report as specified in its charter, which is required by forms filed with the SEC.", "label": "Entity Registrant Name", "terseLabel": "Entity Registrant Name" } } }, "localname": "EntityRegistrantName", "nsuri": "http://xbrl.sec.gov/dei/2022", "presentation": [ "http://www.elevancehealth.com//20230802/taxonomy/role/DocumentDocumentAndEntityInformation" ], "xbrltype": "normalizedStringItemType" }, "dei_EntityTaxIdentificationNumber": { "auth_ref": [ "r1" ], "lang": { "en-us": { "role": { "documentation": "The Tax Identification Number (TIN), also known as an Employer Identification Number (EIN), is a unique 9-digit value assigned by the IRS.", "label": "Entity Tax Identification Number", "terseLabel": "Entity Tax Identification Number" } } }, "localname": "EntityTaxIdentificationNumber", "nsuri": "http://xbrl.sec.gov/dei/2022", "presentation": [ "http://www.elevancehealth.com//20230802/taxonomy/role/DocumentDocumentAndEntityInformation" ], "xbrltype": "employerIdItemType" }, "dei_LocalPhoneNumber": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Local phone number for entity.", "label": "Local Phone Number", "terseLabel": "Local Phone Number" } } }, "localname": "LocalPhoneNumber", "nsuri": "http://xbrl.sec.gov/dei/2022", "presentation": [ "http://www.elevancehealth.com//20230802/taxonomy/role/DocumentDocumentAndEntityInformation" ], "xbrltype": "normalizedStringItemType" }, "dei_PreCommencementIssuerTenderOffer": { "auth_ref": [ "r3" ], "lang": { "en-us": { "role": { "documentation": "Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act.", "label": "Pre Commencement Issuer Tender Offer", "terseLabel": "Pre Commencement Issuer Tender Offer" } } }, "localname": "PreCommencementIssuerTenderOffer", "nsuri": "http://xbrl.sec.gov/dei/2022", "presentation": [ "http://www.elevancehealth.com//20230802/taxonomy/role/DocumentDocumentAndEntityInformation" ], "xbrltype": "booleanItemType" }, "dei_PreCommencementTenderOffer": { "auth_ref": [ "r4" ], "lang": { "en-us": { "role": { "documentation": "Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act.", "label": "Pre Commencement Tender Offer", "terseLabel": "Pre Commencement Tender Offer" } } }, "localname": "PreCommencementTenderOffer", "nsuri": "http://xbrl.sec.gov/dei/2022", "presentation": [ "http://www.elevancehealth.com//20230802/taxonomy/role/DocumentDocumentAndEntityInformation" ], "xbrltype": "booleanItemType" }, "dei_Security12bTitle": { "auth_ref": [ "r0" ], "lang": { "en-us": { "role": { "documentation": "Title of a 12(b) registered security.", "label": "Security 12b Title", "terseLabel": "Security 12b Title" } } }, "localname": "Security12bTitle", "nsuri": "http://xbrl.sec.gov/dei/2022", "presentation": [ "http://www.elevancehealth.com//20230802/taxonomy/role/DocumentDocumentAndEntityInformation" ], "xbrltype": "securityTitleItemType" }, "dei_SecurityExchangeName": { "auth_ref": [ "r2" ], "lang": { "en-us": { "role": { "documentation": "Name of the Exchange on which a security is registered.", "label": "Security Exchange Name", "terseLabel": "Security Exchange Name" } } }, "localname": "SecurityExchangeName", "nsuri": "http://xbrl.sec.gov/dei/2022", "presentation": [ "http://www.elevancehealth.com//20230802/taxonomy/role/DocumentDocumentAndEntityInformation" ], "xbrltype": "edgarExchangeCodeItemType" }, "dei_SolicitingMaterial": { "auth_ref": [ "r5" ], "lang": { "en-us": { "role": { "documentation": "Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as soliciting material pursuant to Rule 14a-12 under the Exchange Act.", "label": "Soliciting Material", "terseLabel": "Soliciting Material" } } }, "localname": "SolicitingMaterial", "nsuri": "http://xbrl.sec.gov/dei/2022", "presentation": [ "http://www.elevancehealth.com//20230802/taxonomy/role/DocumentDocumentAndEntityInformation" ], "xbrltype": "booleanItemType" }, "dei_TradingSymbol": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Trading symbol of an instrument as listed on an exchange.", "label": "Trading Symbol", "terseLabel": "Trading Symbol" } } }, "localname": "TradingSymbol", "nsuri": "http://xbrl.sec.gov/dei/2022", "presentation": [ "http://www.elevancehealth.com//20230802/taxonomy/role/DocumentDocumentAndEntityInformation" ], "xbrltype": "tradingSymbolItemType" }, "dei_WrittenCommunications": { "auth_ref": [ "r6" ], "lang": { "en-us": { "role": { "documentation": "Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as written communications pursuant to Rule 425 under the Securities Act.", "label": "Written Communications", "terseLabel": "Written Communications" } } }, "localname": "WrittenCommunications", "nsuri": "http://xbrl.sec.gov/dei/2022", "presentation": [ "http://www.elevancehealth.com//20230802/taxonomy/role/DocumentDocumentAndEntityInformation" ], "xbrltype": "booleanItemType" } }, "unitCount": 0 } }, "std_ref": { "r0": { "Name": "Exchange Act", "Number": "240", "Publisher": "SEC", "Section": "12", "Subsection": "b", "role": "http://www.xbrl.org/2003/role/presentationRef" }, "r1": { "Name": "Exchange Act", "Number": "240", "Publisher": "SEC", "Section": "12", "Subsection": "b-2", "role": "http://www.xbrl.org/2003/role/presentationRef" }, "r2": { "Name": "Exchange Act", "Number": "240", "Publisher": "SEC", "Section": "12", "Subsection": "d1-1", "role": "http://www.xbrl.org/2003/role/presentationRef" }, "r3": { "Name": "Exchange Act", "Number": "240", "Publisher": "SEC", "Section": "13e", "Subsection": "4c", "role": "http://www.xbrl.org/2003/role/presentationRef" }, "r4": { "Name": "Exchange Act", "Number": "240", "Publisher": "SEC", "Section": "14d", "Subsection": "2b", "role": "http://www.xbrl.org/2003/role/presentationRef" }, "r5": { "Name": "Exchange Act", "Number": "240", "Publisher": "SEC", "Section": "14a", "Subsection": "12", "role": "http://www.xbrl.org/2003/role/presentationRef" }, "r6": { "Name": "Securities Act", "Number": "230", "Publisher": "SEC", "Section": "425", "role": "http://www.xbrl.org/2003/role/presentationRef" } }, "version": "2.2" } ZIP 18 0001193125-23-205527-xbrl.zip IDEA: XBRL DOCUMENT begin 644 0001193125-23-205527-xbrl.zip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